<- Go Home
PainReform Ltd.
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Market Cap
$1.6M
Volume
16.8K
Cash and Equivalents
$2.8M
EBITDA
-$17.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$80.64
52 Week Low
$1.73
Dividend
N/A
Price / Book Value
-0.20
Price / Earnings
-0.02
Price / Tangible Book Value
-0.20
Enterprise Value
-$1.1M
Enterprise Value / EBITDA
0.06
Operating Income
-$17.8M
Return on Equity
716.67%
Return on Assets
-195.07
Cash and Short Term Investments
$2.8M
Debt
$59.0K
Equity
-$2.0M
Revenue
N/A
Unlevered FCF
-$4.9M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium